¶ Reliance Life Sciences
.png)
Reliance Life Sciences Pvt. Ltd. is an Indian biopharmaceutical company based in Mumbai, India.
¶ History
Reliance is developing a “second-generation” two antigen subunit protein COVID-19 vaccine called RelCoVax.[1] On September 21, 2021, Dr. Robert Malone pitched RelCoVax to an online audience at the Vaccines Summit-2021.[2][3]
¶ External links
Phatarphekar, A., Vidyadhar Reddy, G. E. C., Gokhale, A., Karanam, G., Kuchroo, P., Shinde, K., Masand, G., Pagare, S., Khadpe, N., Pai, S. S., Vijayan, V., Ramnath, R. L., Pratap Reddy, K., Rao, P., Harinarayana Rao, S., & Ramana, V. (2022). RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice. Vaccine, 40(32), 4522–4530. https://doi.org/10.1016/j.vaccine.2022.06.026 ↩︎
Housatonic. (2023, February 6). (Sep 21 2021) Robert malone: “RelCovax, 2ndGen multivalent SARS-CoV-2 vaccine candidate” (Summit). Rumble. https://web.archive.org/web/20230208073041/https://rumble.com/v28ntb2-sep-21-2021-robert-malone-relcovax-2ndgen-multivalent-sars-cov-2-vaccine-ca.html ↩︎
Speakers. Vaccines Summit-2021. Retrieved April 20, 2021, from https://web.archive.org/web/20210420005033/https://scientiameetings.com/conferences/vaccines/speakers ↩︎